Article Sidebar

PDF (Tiếng Việt)
Published: 2025-06-16
Abstract Views: 0
Views PDF (Tiếng Việt): 0
DOI: https://doi.org/10.52852/tcncyh.v191i6.3291
Issue
Vol. 191 No. 6 (2025)
Section
Các bài báo
How to Cite
Thái, P. V., & Tuynh, C. V. (2025). The role of 18FDG-PET/CT in staging non-small cell lung cancer in patients undergoing curative surgery. Journal of Medical Research, 191(6), 75-83. https://doi.org/10.52852/tcncyh.v191i6.3291

The role of 18FDG-PET/CT in staging non-small cell lung cancer in patients undergoing curative surgery

Pham Van Thai, Chu Van Tuynh

Main Article Content

Abstract

This study aims to evaluate the diagnostic value of 18FDG-PET/CT in tumor and lymph node staging in patients with non-small cell lung cancer (NSCLC) undergoing curative surgery. A descriptive study was conducted on 82 patients with stage I-IIIA NSCLC who underwent preoperative 18FDG-PET/CT, with subsequent histopathological correlation after surgery. The results showed that tumor staging on 18FDG-PET/CT was concordant with postoperative histopathology in 92.7% of all cases, while lymph node staging was concordant in 91.4% of cases. The sensitivity, specificity, positive predictive value, negative predictive value, and overall accuracy of 18FDG-PET/CT for detecting nodal metastases were 75.0%, 98.5%, 85.7%, 97.0%, and 96.0%, respectively. The overall staging concordance rate was 85.4%. These findings indicate that 18FDG- PET/CT has high diagnostic value in T and N staging of NSCLC in patients eligible for curative surgery, when compared with postoperative histopathological results.

Article Details

Keywords

18FDG-PET/CT, non-small cell lung cancer, staging, curative surgery

References

1. International Agency for Research on Cancer. Cancer Today. Accessed March 2, 2025. https://gco.iarc.fr/today/en/dataviz/bars?types=0_1&mode=cancer&group_populations=1&sort_by=value1&key=total&populations=900.
2. NCCN Clinical Practice Guidelines in Oncology. Non-Small Cell Lung Cancer. Version 3.2025 -January 14, 2025
3. Huỳnh Quang Huy. Nghiên cứu trị số SUVmax của hạch di căn ung thư phổi biểu mô tuyến trên PET/CT. Tạp chí Y học Việt Nam. 2018; 465(1): 3-6
4. Mai Trọng Khoa, Trần Hải Bình. Giá trị của PET/CT trong chẩn đoán ung thư phổi không tế bào nhỏ. Tạp chí Ung thư học Việt Nam. 2011; 2: 101-108.
5. Vũ Hồng Thăng, Đỗ Thị Thu Nga, Trần Thắng, Phạm Lâm Sơn. Giá trị của PET/CT trong chẩn đoán giai đoạn bệnh ung thư phổi tại Bệnh viện K. Tạp chí Nghiên cứu Y học, Đại học Y Hà Nội. 2023; 164(3):188-193.
6. Antoch G, et al. Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. Radiology. 2003: 229(2): 526-533. DOI: 10.1148/radiol.2292021598.
7. Schmidt-Hansen M, Baldwin D. R, Hasler, et al. PET-CT for assessing mediastinal lymph node involvement in patients with suspected resectable non-small cell lung cancer. Cochrane Database of Systematic Reviews. 2014 Nov 13; 2014(11): CD009519. DOI: 10.1002/14651858.CD009519.pub2.
8. Akram Al Ibraheem, Nader Hirmas, Stefano Fantiet, et al. Impact of 18FDG- PET/CT, CT and EBUS/TBNA on preoperative mediastinal nodal staging of NSCLC. BMC Med Imaging. 2021 Mar 17; 21(1):49. DOI: 10.1186/s12880-021-00580-w.
9 .Gail E. Darling, Donna E. Maziak, Richard I. Inculet, et al. Positron Emission Tomography-Computed Tomography Compared with Invasive Mediastinal staging in Non-small Cell Lung Cancer. J Thorac Oncol. 2011 Aug; 6(8): 1367-1372. DOI: 10.1097/JTO.0b013e318220c912.
10. Birim O, Kappetein A.P, Stijnen T, et al. Meta-analysis of positron emission tomographic and computed tomographic imaging in detecting mediastinal lymph node metastases in nonsmall cell lung cancer. Ann Thorac Surg. 2005 Jan; 79(1): 375-82. DOI: 10.1016/j.athoracsur.2004.06.041.
11. Toloza E.M, Harpole L, McCrory D.C. Noninvasive staging of non-small cell lung cancer: a review of the current evidence. Chest. 2003 Jan; 123(1 Suppl): 137S-146S. DOI: 10.1378/chest.123.1_suppl.137.
12. Zhou X, Chen R, Huang G, Liu J. Potential clinical value of PET/CT in predicting occult nodal metastasis in T1-T2N0M0 lung cancer patients staged by PET/CT. Oncotarget. 2017 Jul 25; 8(47): 82437–82445. DOI: 10.18632/oncotarget.19535.
13. Asha Kandathil, Fernando U. Kay, et al, (2018). Role of FDG-PET/CT in the Eighth Edition of TNM Staging of Non-Small Cell Lung. Cancer Radio Graphics. 2018; 38(7): 2134-2149. DOI: 10.1148/rg.2018180060.
14. Mohsen F. FDG-PET/CT in the Staging of Lung Cancer. Curr Radiopharm. 2020 Dec; 13(3): 195-203. DOI: 10.2174/1874471013666191223153755.
15. Julian M.M.R, Nikolaj F, Stephanie B, et al. FDG-PET/CT for pretherapeutic lymph node staging in non-small cell lung cancer: A tailored approach to the ESTS/ESMO guideline workflow. Lung Cancer. 2021; 157: 66-74. DOI:10.1016/j.lungcan.2021.05.003.